Go to content

News

Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease 

Read about Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease 

Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025 

Read about Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025 

Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development

Read about Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development

Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025

Read about Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025

Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025

Read about Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025

Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024

Read about Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024

PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery

Read about PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery

PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection

Read about PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection

PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT

Read about PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT

PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA

Read about PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA